

Proceeding Paper

Exploring Green Tea Polyphenols Against Penicillin-Binding Proteins (PBPs) as Prospective Targets for Peptic Ulcer Treatment: In-Silico Analysis [†]

Parasuram Ayyappan, Janavi Rao, Pratik Ganpule, Rakesh Somani and Suraj N. Mali *

Department of Pharmaceutical Chemistry, School of Pharmacy, D.Y. Patil University (Deemed to be University), Nerul, Navi Mumbai 400706, India; email1@email.com (P.A.); email2@email.com (J.R.); email1@email.com (P.G.); email2@email.com (R.S.)

* Correspondence: suraj.mali@dypatil.edu.in

[†] Presented at the 29th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-29);

Available online: <https://sciforum.net/event/ecsoc-29>.

Abstract

Peptic ulcer disease, affecting almost 20% of the worldwide population, depicts an urgent need for effective treatment due to the limited therapeutic options available and the side effects associated with current drugs. The disease is often linked with *Helicobacter pylori* infection and NSAID usage, both of which compromise the mucosal lining of the stomach. There is growing evidence that dietary polyphenols can contribute to the prevention and management of various chronic diseases, including cancer and gastrointestinal disorders. Among these, green tea has garnered significant attention due to its rich polyphenolic content and associated health benefits. The abundance of green tea polyphenols (GTPs) exhibits chemoprotective, antimicrobial, and antioxidant properties. This study explores a set of 65 GTPs against penicillin-binding proteins (PBPs) as a molecular target to prevent peptic ulceration. Our molecular docking analysis revealed that the polyphenol 'Epigallocatechin gallate' (EGCG) exhibited effective binding affinity towards PBPs (PDB code: 1QMF) with a docking score of (-17.23 kcal/mol), followed then by Theaflavin-3-gallate (-16.57 kcal/mol), and Epigallocatechin (-15.91 kcal/mol). In-silico ADME profiling indicated favorable pharmacokinetics for EGCG, including no AMES toxicity, low hERG inhibition, and good intestinal absorption. Our study highlights EGCG as a potential inhibitor of *H. pylori*, providing a promising natural therapeutic candidate for the management of peptic ulcer disease.

Keywords: flavonoids; *Helicobacter pylori*; green tea polyphenols; docking

Academic Editor: Suraj Mali

Published: date

Citation: Ayyappan, P.; Rao, J.; Ganpule, P.; Somani, R.; Mali, S.N. Exploring Green Tea Polyphenols Against Penicillin-Binding Proteins (PBPs) as Prospective Targets for Peptic Ulcer Treatment: In-Silico Analysis. *Chem. Proc.* **2025**, volume number, x.

<https://doi.org/10.3390/xxxxx>

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Helicobacter pylori infect up to 80% of children in developing countries, spreading via fecal-oral or oral-oral routes. Prevalence is higher with poor sanitation, aging, and among African Americans and Hispanics in the U.S., with no sex difference. Infection persists lifelong if untreated [1]. About 10–15% develop peptic ulcers, while gastric cancer is rarer and influenced by additional factors. *H. pylori* is also linked to gastric non-Hodgkin's lymphomas, though these constitute under 3% of malignancies [2]. This bacillus is a spiral shaped and known as a major etiological cause for chronic gastritis. Even though, we have conventional therapy, there are many severe side effects associated raising concerns

regarding drug toxicity. This conventional therapy would also have a major issue of drug resistance [3], henceforth there is an urgent need to develop alternative strategies comprising use of plant-derived extracts and phytochemicals, which recently have gained interest [4]. Flavonoid-rich extracts are of special focus due to their multiple mechanisms of action against *H. pylori*. Besides antibacterial activity, flavonoids enhance mucosal defense by exerting cytoprotective, antioxidative, and anti-inflammatory effects. Individual flavonoids often display multi-target anti-ulcer activity, including protection of intestinal barrier integrity, modulation of gastric secretions, regulation of enzymatic activity, immune modulation, and interference with microbial colonization [5]. Penicillin-binding proteins (PBPs), essential for bacterial cell wall maintenance, provide an additional therapeutic target [6]. Their allosteric binding sites facilitate conformational changes that increase substrate accessibility. Identifying inhibitors capable of binding both active and allosteric sites offer a promising therapeutic strategy. Green tea extracts, particularly catechins, exhibit inhibitory effects on *H. pylori* growth in vitro. Studies suggest that green tea intake, either prior to or following infection, can prevent or reduce gastric mucosal inflammation [7–9]. Its polyphenols suppress *H. pylori*-induced proliferation of gastric epithelial cells and inhibit urease activity, an enzyme critical for bacterial colonization and survival [1]. In this study, we evaluated phytomolecules from *Green Tea* against PBPs, exploring dual-site binding interactions to reveal novel inhibitory profiles. Further, in-silico ADME analyses were conducted to assess pharmacokinetic properties, supporting the potential of flavonoids as adjuncts to conventional therapy.

2. Materials and Methods

2.1. Molecular Docking

For the current work, we docked 65 Green Tea phytomolecules (GTPs) from the plant *Camellia sinensis*, reported in various literatures. These phytomolecules would then drawn for their 2D structures in 'ChemDraw 12.0 V' and subsequently converted to their 3D structures using 'Chem3D' and optimized further using 'Avogadro software'. For 3D crystal structure of protein, we downloaded the penicillin-binding protein (PDB code: 1QMF) from the Protein Database Bank (<https://www.rcsb.org/structure/1QMF>; accessed on 20 August 2025). The processing for the protein was done using the 'automated functionality' in 'MzDock V.2', 2025 tool (<https://sourceforge.net/projects/mzdock/>; accessed on 20 August 2025), which is 'a GUI-based pipeline for simulations [10]. The visualization for docking interactions were done through 'BIOVIA Discovery Studio 2025' Visualizer.

2.2. In Silico Drug-Likeness and ADMET Analysis

We have screened top 3 best docked candidates phytomolecules from *C. sinensis* for their theoretical/predicted ADME properties using the 'SwissADME' (<http://www.swissadme.ch>, accessed on 20 August 2025). For toxicity assessments, we used 'admetSAR' (<http://lmmd.ecust.edu.cn:8000/>, accessed on 20 August 2025) [11].

2.3. Boiled Egg Model Analysis

The BOILED-Egg (Brain Or Intestinal Estimated permeation method) model analysis (<http://www.swissadme.ch>, accessed on 20 August 2025), serve as a theoretical estimation of brain access and gastrointestinal absorption profiles for the molecule. Using these two physicochemical parameters, it simultaneously predicts intestinal absorption and brain penetration. Owing to its speed, accuracy, conceptual simplicity, and intuitive graphical output, the model readily supports molecular design. The BOILED-Egg approach is widely applicable, including in drug candidate evaluation and chemical library screening during early drug discovery.

3. Results and Discussion

3.1. Docking Interaction Analyses

Our molecular docking analysis of 65 GTPs on the penicillin-binding protein target suggested that epigallocatechin gallate (EGCG) had highest affinity (−17.23 kcal/mol), followed by Theaflavin-3-gallate (−16.57 kcal/mol), and Epigallocatechin (−15.91 kcal/mol) (Tables 1 and 2).

Docking studies revealed a range of binding affinities (Table 1), with several polyphenolic compounds showing strong interactions. Isotheaflavin (−14.1 kcal/mol), Oolonghomobisflavan B (−12.5 kcal/mol), and Epigallocatechin-3,4-di-O-gallate (−12.0 kcal/mol) exhibited the highest binding scores, stabilized by extensive hydrogen bonding (Thr550, Ser337, Asn397) and hydrophobic contacts (Trp374, Tyr568, Ala551).

Other promising candidates included Myricetin (−11.4 kcal/mol), Epicatechin-3,5-di-O-gallate (−11.4 kcal/mol), Epigallocatechin gallate (−17.23 kcal/mol), and Epiafzelechin-3-O-gallate (−11.0 kcal/mol), all of which engaged in multiple H-bonds with key residues (Gln452, Ser337, His394) along with π - π stacking and van der Waals stabilization. Moderate affinity compounds such as Barringtogenol (−9.3 kcal/mol), Epicatechin gallate (−9.1 kcal/mol), and Isoquercetin (−9.6 kcal/mol) also demonstrated favorable binding. In contrast, smaller molecules like benzaldehyde (−4.8 kcal/mol), cis-3-hexanol (−4.1 kcal/mol), and diphenylamine (−3.9 kcal/mol) showed weak interactions with minimal stabilizing contacts. Docking interactions diagrams (2D and 3D) for top 3 hits have been shown in Figures 1 and 2.

Table 1. Docking interaction energies of selected 65 bio-active molecules and 1 FDA approved drugs for target penicillin-binding proteins (PBPs).

Molecules	Binding Affinity (kcal/mol)	Molecules	Binding Affinity (kcal/mol)
Oolonghomobisflavan A		Theaflavic Acid	−7.21
Theasinensin D	−9.74	Barrigenol R1	
Theaflavin-3-gallate	−16.57	Barringtogenol	−9.3
Isotheaflavin	−14.1	Camelliagenin	−6.41
Epigallocatechin-3,5-Di-O-Gallate	−6.67	Gallocatechin	−6.14
Oolonghomobisflavan B	−12.5	Catechin	−6.01
Cis-3-Hexenol	−4.1	Epicatechin	−5.28
Epigallocatechin-3,4-Di-O-Gallate	−12.0	Epiafzelechin	−4.07
Vicenin 2	−5.33	Quercetin	−9.02
Epicatechin-3,5-Di-O-Gallate	−11.4	Cryptoxanthin	−9.11
Rutin	−5.98	Myricetin	−11.4
Proanthocyanidin	−5.33	Apigenin	−4.99
Pheophytin	−4.22	Nerolidol	−4.36
Benzaldehyde	−4.8	Kaempferol	−3.10
Epitheflavic Acid 3'-Gallate	−4.19	Theanine	−2.90
Epigallocatechin Gallate	−17.23	Ascorbic Acid	−2.11
Theasinensin E	−7.32	Quinic Acid	−1.09
Myricitrin	−11.4	Succinic Acid	−1.7
Theaflavin	−2.23	Methyl Salicylate	−5.37
Epicatechin Gallate	−9.1	Theobromine	−5.21
Kaempferitrin	−4.73	Caffeine	−5.78
Isoquercetin	−9.6	Xanthine	−5.59
Epiafzelechin 3-O-Gallate	−11.0	Linalool Oxide	−5.88
Pheophorbide	−7.34	Phenylacetaldehyde	−5.71
Epigallocatechin 3-O-P-Coumarate	−7.25	Methylxanthine	−5.66
Pheophorbide	−5.55	Theophylline	−5.69
Oxalic Acid	−5.03	Geraniol	−5.31

Figure 2. 3D docking interaction diagrams for (a) epigallocatechin gallate; (b) Theaflavin-3-gallate, (c) Epigallocatechin and (d) standard drug, Amoxicillin, respectively against PBP.

3.2. The ADME Analysis and BOILED-Egg

The in-silico ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles of the top three docked hits are summarized in Table 3. The ADME analysis shows clear differences in drug-likeness among the compounds from Green Tea. Molecules with low TPSA (<90 Å²) and moderate lipophilicity (MLOGP ~1–3), such as apigenin, benzaldehyde, caffeine, geraniol, linalool, and methyl salicylate, exhibited high GI absorption and, in several cases, BBB permeability (apigenin, benzaldehyde, cis-3-hexenol, diphenylamine). Larger polyphenols (e.g., epigallocatechin gallates, rutin, proanthocyanidins) with high TPSA (>150 Å²) denoted poor GI absorption, no BBB penetration, multiple Lipinski violations, and reduced bioavailability scores (≤ 0.17), limiting oral drug potential (Supplementary file, Table S1).

Most small molecules are not P-gp substrates and generally non-inhibitors of major CYP isoforms, except for certain flavonoids (e.g., kaempferol, quercetin, myricetin) which inhibited CYP1A2, CYP2C9, or CYP3A4, suggesting possible drug–drug interaction liabilities. Compounds with good solubility and no Lipinski violations (e.g., ascorbic acid, theophylline, oxalic/succinic acid) demonstrated favorable oral bioavailability, though not all cross the BBB. Theaflavin-3-gallate, Epigallocatechin, and Epigallocatechin Gallate (EGCG) demonstrated favorable intestinal absorption (Figure 3), no Blood–Brain Barrier permeability, and were predicted to be non-carcinogenic, non-AMES toxic, with class IV acute oral toxicity.

Table 3. Predictive ADMET analysis for top 3 best docked hits.

Properties	Theaflavin-3-gallate	Epigallocatechin	Epigallocatechin Gallate (EGCG) *
CYP450 2C9 Substrate	Non-substrate	Non-substrate	Non-substrate
CYP450 2D6 Substrate	Non-substrate	Non-substrate	Non-substrate
CYP450 3A4 Substrate	Non-substrate	Non-substrate	Non-substrate
Human Ether-a-go-go-Related Gene Inhibition	Weak inhibitor	Weak inhibitor	Weak inhibitor
AMES Toxicity	Non-AMES toxic	Non-AMES toxic	Non-AMES toxic
Carcinogens	None	None	None
Acute Oral Toxicity	IV	IV	IV
P-glycoprotein Inhibitor	Non-inhibitor	Non-inhibitor	Non-inhibitor
Rat Acute Toxicity (LD ₅₀ , mol/kg)	2.6693	1.8700	2.6643
Human Intestinal Absorption	+	+	+
AlogP	3.19	1.25	2.23
H-Bond Acceptor	16	7	11
H-Bond Donor	11	6	8
Tetrahymena pyriformis (pIGC50 (ug/L))	0.595	0.792	0.913
Blood Brain Barrier	-	-	-

* Best docked.




Figure 3. BOILED-Egg model analysis for the best docked Epigallocatechin Gallate (EGCG).

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/doi/s1>, Table S1.

Author Contributions: Conceptualization, P.A. and J.R.; methodology P.G. and S.N.M.; writing—original draft preparation, S.N.M. and R.S.; writing—review and editing S.N.M. and R.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data used in this work is already available in the manuscript.

Acknowledgments: Author thanks, 'D. Y. Patil University, Navi Mumbai, India' and School of Pharmacy, DYPU, Navi Mumbai, India for the provision of CADD facility.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Yadav, S.; Pandey, A.; Mali, S.N. From Lab to Nature: Recent Advancements in the Journey of Gastroprotective Agents from Medicinal Chemistry to Phytotherapy. *Eur. J. Med. Chem.* **2024**, *272*, 116436.
2. Sugano, K.; Tack, J.; Kuipers, E.J.; Graham, D.Y.; El-Omar, E.M.; Miura, S.; Haruma, K.; Asaka, M.; Uemura, N.; Malfertheiner, P. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* **2015**, *64*, 1353–1367.
3. Dadgostar, P. Antimicrobial resistance: Implications and costs. *Infect. Drug Resist.* **2019**, *12*, 3903–3910.
4. Guerra-Valle, M.; Orellana-Palma, P.; Petzold, G. Plant-based polyphenols: Anti-Helicobacter pylori effect and improvement of gut microbiota. *Antioxidants* **2022**, *11*, 109.
5. Tan, A.; Scortecchi, K.C.; Boylan, F. A Review on Flavonoids as Anti-Helicobacter pylori Agents. *Appl. Sci.* **2025**, *15*, 3936. <https://doi.org/10.3390/app15073936>.
6. Gerrits, M.M.; Schuijffel, D.; Van Zwet, A.A.; Kuipers, E.J.; Vandenbroucke-Grauls, C.M.J.E.; Kusters, J.G. Alterations in penicillin-binding protein 1A confer resistance to β -lactam antibiotics in Helicobacter pylori. *Antimicrob. Agents Chemother.* **2002**, *46*, 2229–2233.
7. Makarewicz, M.; Drożdż, I.; Tarko, T.; Duda-Chodak, A. The Interactions between polyphenols and microorganisms, especially gut microbiota. *Antioxidants* **2021**, *10*, 188.
8. Filosa, S.; di Meo, F.; Crispi, S. Polyphenols-gut microbiota interplay and brain neuromodulation. *Neural Regen. Res.* **2018**, *13*, 154–169.
9. Guerra-Valle, M.; Orellana-Palma, P.; Petzold, G. Plant-Based Polyphenols: Anti-Helicobacter pylori Effect and Improvement of Gut Microbiota. *Antioxidants* **2022**, *11*, 109. <https://doi.org/10.3390/antiox11010109>.

10. Kabier, M.; Gambacorta, N.; Trisciuzzi, D.; Kumar, S.; Nicolotti, O.; Mathew, B. MzDOCK: A free ready-to-use GUI-based pipeline for molecular docking simulations. *J. Comput. Chem.* **2024**, *45*, 1980–1986.
11. Yang, H.; Lou, C.; Sun, L.; Li, J.; Cai, Y.; Wang, Z.; Li, W.; Liu, G.; Tang, Y. admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics* **2019**, *35*, 1067–1069.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.